Skip to main content
Smart Investors Daily
Danaher Corporation logo

NYSE · DHR

Danaher Corporation

Healthcare · Medical - Diagnostics & Research

$228.58

Down-$1.02 (-0.45%)

Updated Nov 20, 2026, 1:49 AM

SID Score

5.8/10

Composite research score

Smart Money

52/100

Neutral

Market cap
166.5B
P/E ratio
47.14
Dividend yield
0.54%
52-week range
$160.93 – $242.80
Volume
2.94M
Avg. volume
4.18M

Price performance · DHR

DHR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

DHR closed at $228.58 after 20 trading sessions, down 0.51% for the selected period.

Last close
$228.58
Period change
-0.51%
Period low
$225.77
Period high
$236.98
Daily close
View OHLC price history
DHR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$227.00$230.00$225.44$228.582.94M
Nov 17, 2026$228.49$231.30$225.07$225.773.56M
Nov 16, 2026$233.54$233.75$229.67$229.913.23M
Nov 13, 2026$232.99$233.76$229.915$233.023.36M
Nov 12, 2026$235.42$235.655$231.83$232.162.38M
Nov 11, 2026$236.00$237.95$234.11$235.313.23M
Nov 10, 2026$235.37$236.86$231.74$236.113.4M
Nov 9, 2026$231.63$236.6618$228.37$235.123.63M
Nov 6, 2026$222.96$230.66$222.96$230.254.06M
Nov 5, 2026$237.45$238.45$225.86$226.345.14M
Nov 4, 2026$235.33$236.67$229.92$234.933.06M
Nov 3, 2026$228.70$233.20$227.20$230.112.69M
Nov 2, 2026$234.20$234.29$227.53$227.973.16M
Oct 30, 2026$238.46$238.46$230.46$232.233.76M
Oct 29, 2026$234.00$237.62$232.86$236.982.7M
Oct 28, 2026$231.00$238.03$229.55$234.073.14M
Oct 27, 2026$231.00$234.00$229.3201$232.002.5M
Oct 26, 2026$230.94$233.95$230.60$232.973.12M
Oct 23, 2026$229.17$230.66$225.60$230.503.94M
Oct 22, 2026$233.80$238.128$228.165$229.757.07M

Latest DHR news

The latest Smart Investors Daily articles mentioning DHR.

DHR research

Overview

Company profile and research snapshot.

Company profile

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$249.71
Implied upside
—
Analysts
16
DHR recent ratings
DateFirmRatingTarget
Oct 22, 2026StifelBuy—
Oct 22, 2026TD CowenBuy—
Oct 22, 2026JP MorganOverweight—
Oct 22, 2026BairdOutperform—
Oct 22, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 19, 2026

A $22 Billion Hedge Fund Just Bought These 3 Stocks

Key TakeawaysA $22 billion hedge fund opened new positions in Amazon, Danaher and Meta in the third quarter, and they’re now its three largest holdings. The three made up 22% of its 13F stocks at Sept.

Yahoo · Nov 18, 2026

Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push

Danaher (NYSE:DHR) is focusing on commercial execution, innovation and acquisitions as it seeks faster core growth and market-share gains, company leader Julie said during a discussion with Tycho Peterson of the Life Science team. Julie, who was identified only by her first name in the transcript,

AI research layers

Interpretive context generated from the platform’s current data sources.

Danaher Corporation Stock Performance

Danaher Corporation shares closed at $228.41, declining 1.12% in the most recent trading session, per SID market data. Despite the daily pullback, the stock has demonstrated positive momentum over the near term, gaining 0.6% over the past month and 6.75% over the trailing three months. However, DHR remains down 5.12% over the past twelve months, underperforming the broader healthcare sector. From a technical standpoint, the stock trades above both its 50-day moving average of $223.36 and its 200-day moving average of $200.14, according to Massive/Polygon data, suggesting the intermediate-term trend remains constructive. The 14-day relative strength index sits at 41.6, indicating the stock is approaching oversold territory without yet triggering a classic oversold signal. Danaher carries a beta of 0.923, reflecting slightly lower volatility than the broader market. Average daily trading volume stands at approximately 4.18 million shares.

Danaher Corporation Valuation Analysis

Danaher Corporation currently commands a market capitalization of approximately $166.5 billion, positioning it among the largest companies in the healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 47.14, a significant premium relative to both the broader market and many healthcare sector peers, reflecting investor expectations for sustained long-term earnings growth. However, the PEG ratio of 14.87 suggests the elevated P/E multiple is not well supported by near-term earnings growth rates, according to SEC filings. The price-to-book ratio stands at 3.23, indicating the market values the company at more than three times its book value. Danaher offers a modest dividend yield of approximately 0.53%, consistent with the company's historical preference for reinvesting capital into acquisitions and organic growth initiatives rather than returning significant cash to shareholders through dividends.

Smart Money Activity for DHR

Danaher Corporation's composite smart money score stands at 52 out of 100, reflecting a neutral overall signal, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating strong conviction among large fund managers and signaling robust institutional accumulation patterns. Congressional trading activity scores 12 out of 25, suggesting moderate legislative interest in the stock. The insider activity score registers at 6.1 out of 25, with SEC Form 4 filings showing 20 insider transactions over the past 90 days, comprising 12 purchases and 8 sales. The net buying activity among corporate insiders represents a modestly positive signal, though the overall insider score remains subdued. Dark pool activity scores 8.5 out of 25, according to 13F institutional filings, indicating below-average levels of off-exchange block trading. The divergence between high institutional conviction and lower insider and dark pool scores contributes to the overall neutral composite reading.

Danaher Corporation Earnings Outlook

Danaher Corporation has demonstrated a consistent pattern of exceeding analyst expectations across its most recent quarterly earnings reports. In the latest reported quarter, the company posted earnings per share of $2.11, surpassing the consensus estimate of $1.92 by $0.19, representing a 9.9% upside surprise, according to company earnings reports. The prior quarter showed EPS of $1.94 against an estimate of $1.84, delivering a $0.10 positive surprise. The quarter before that produced EPS of $2.06 versus the $1.94 estimate, a $0.12 beat. This three-quarter streak of earnings outperformance demonstrates management's ability to deliver results above Street expectations. Looking ahead, analysts project EPS of $1.92 for the upcoming reporting period, per analyst estimates. Given the established trend of beats averaging approximately $0.14 per quarter, the consensus figure may represent a conservative baseline for forward earnings expectations.

Wall Street Analyst Ratings for DHR

Wall Street consensus on Danaher Corporation remains decisively bullish, with multiple major firms reiterating positive ratings following the company's most recent earnings report. On October 22, JP Morgan maintained its Overweight rating, while Stifel and TD Cowen each reiterated Buy recommendations, according to Wall Street analyst reports. Additionally, Baird maintained its Outperform rating, and Barclays reaffirmed its Overweight stance on the same date. Notably, all five analyst actions represented reiterations of existing positive ratings rather than upgrades, per SID consensus data, indicating sustained long-term confidence rather than a shift in sentiment. The unanimity across five prominent sell-side institutions is significant, as no downgrades or neutral ratings were issued in the most recent coverage cycle. The consistent bullish positioning across both U.S. and European investment banks suggests broad institutional agreement on Danaher's strategic positioning within the life sciences and diagnostics markets despite elevated valuation multiples.